Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2017: 3.556

CiteScore 2017: 2.34

SCImago Journal Rank (SJR) 2017: 1.114
Source Normalized Impact per Paper (SNIP) 2017: 1.188

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 55, Issue 8

Issues

Effects of apixaban on prothrombin time, activated partial thromboplastin time and anti-Xa assays: a European survey

Tuukka A. Helin
  • Coagulation Disorders Unit, Clinical Chemistry, HUSLAB Laboratory Services, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Anja Pakkanen / Riitta Lassila
  • Coagulation Disorders Unit, Hematology and Clinical Chemistry (HUSLAB Laboratory Services), Helsinki University Hospital, University of Helsinki, Helsinki, Finland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Lotta Joutsi-Korhonen
  • Corresponding author
  • Coagulation Disorders Unit, Clinical Chemistry and Hematology, HUSLAB Laboratory Services, Helsinki University Hospital, University of Helsinki, POB 720, 00029 Helsinki, Finland
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2016-12-17 | DOI: https://doi.org/10.1515/cclm-2016-0742

References

  • 1.

    Hillarp A, Gustafsson KM, Faxalv L, Strandberg K, Baghaei F, Fagerberg Blixter I, et al. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. J Thromb Haemost 2014;12:1545–53.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 2.

    Helin TA, Pakkanen A, Lassila R, Joutsi-Korhonen L. Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories. Clin Chem 2013;59:807–14.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 3.

    Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, Horellou MH, Laporte S, et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost 2014;111:240–8.PubMedCrossrefGoogle Scholar

  • 4.

    Bonar R, Favaloro EJ, Mohammed S, Ahuja M, Pasalic L, Sioufi J, et al. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology 2016;48:60–71.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 5.

    Delavenne X, Mismetti P, Basset T. Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. J Pharm Biomed Anal 2013;78:150–3.PubMedWeb of ScienceGoogle Scholar

  • 6.

    Skeppholm M, Al-Aieshy F, Berndtsson M, Al-Khalili F, Ronquist-Nii Y, Soderblom L, et al. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation. Thromb Res 2015;136:148–53.CrossrefPubMedGoogle Scholar

  • 7.

    Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban - an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 2011;32:183–7.Web of ScienceCrossrefPubMedGoogle Scholar

About the article

Corresponding author: Lotta Joutsi-Korhonen, MD, PhD, Coagulation Disorders Unit, Clinical Chemistry and Hematology, HUSLAB Laboratory Services, Helsinki University Hospital, University of Helsinki, POB 720, 00029 Helsinki, Finland, Phone: + 358 50 427 2402, Fax: + 358 9 471 74016


Received: 2016-08-20

Accepted: 2016-11-09

Published Online: 2016-12-17

Published in Print: 2017-07-26


Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: Lyophilized apixaban samples were kindly donated by Pfizer Finland. No other research funding was obtained.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 55, Issue 8, Pages e178–e180, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2016-0742.

Export Citation

©2017 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Tuukka A. Helin, Lauri Virtanen, Mikko Manninen, Jarkko Leskinen, Juhana Leppilahti, Lotta Joutsi-Korhonen, and Riitta Lassila
Journal of Thrombosis and Thrombolysis, 2017, Volume 43, Number 4, Page 562

Comments (0)

Please log in or register to comment.
Log in